At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 35 enrolled
Drug / intervention
Gemcitabine, Irinotecan, Panitumumabdrug
Likely dose
Gemcitabine, Irinotecan, Panitumumab 1000 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Combination of Gemcitabine (Fixed Dose-rate Infusion, FDR), Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma
In Brief
A Phase 2 clinical trial evaluating Gemcitabine, Irinotecan, Panitumumab for Biliary Cancer and Cholangiocarcinoma. Completed, enrolled 35 participants across 1 site.
Detailed Summary
This study evaluates the combination chemotherapy with gemcitabine, irinotecan and panitumumab in patients with advanced biliary cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBiliary Cancer, Cholangiocarcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedJul 2009
Primary CompletionSep 2014
Study CompletionSep 2014
TodayJul 2026
First PostedJul 29, 2009
Enrollment StartApr 1, 2009
Primary CompletionSep 1, 2014
Study CompletionSep 26, 2014
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 16.9 years ago
Interventions
Gemcitabine, Irinotecan, Panitumumabdrug
Gemcitabine 1000 mg/m2 over 100 minutes(Days 1, 8), irinotecan 100 mg/m2 IV over 60 minutes(days 1, 8) and panitumumab 9 mg/kg IV (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.